Arvinas, Inc. Logo

Arvinas, Inc.

ARVN

(1.0)
Stock Price

22,48 USD

-25.27% ROA

-55.59% ROE

-5.73x PER

Market Cap.

1.769.748.018,00 USD

0.35% DER

0% Yield

-346.62% NPM

Arvinas, Inc. Stock Analysis

Arvinas, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Arvinas, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.41x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-54.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-27.09%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-14) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Arvinas, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Arvinas, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Arvinas, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Arvinas, Inc. Revenue
Year Revenue Growth
2016 6.669.024
2017 7.578.876 12.01%
2018 14.323.920 47.09%
2019 42.976.478 66.67%
2020 21.801.777 -97.12%
2021 46.700.000 53.32%
2022 131.400.000 64.46%
2023 138.400.000 5.06%
2023 78.500.000 -76.31%
2024 306.000.000 74.35%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Arvinas, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 19.942.194
2017 28.792.902 30.74%
2018 45.193.830 36.29%
2019 67.193.830 32.74%
2020 108.355.853 37.99%
2021 180.400.000 39.94%
2022 315.000.000 42.73%
2023 343.600.000 8.32%
2023 379.700.000 9.51%
2024 374.800.000 -1.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Arvinas, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 3.196.250
2017 3.546.241 9.87%
2018 12.932.168 72.58%
2019 27.307.162 52.64%
2020 38.303.401 28.71%
2021 61.600.000 37.82%
2022 79.600.000 22.61%
2023 90.400.000 11.95%
2023 100.300.000 9.87%
2024 125.200.000 19.89%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Arvinas, Inc. EBITDA
Year EBITDA Growth
2016 -13.949.134
2017 -23.657.325 41.04%
2018 -43.802.078 45.99%
2019 -51.524.514 14.99%
2020 -124.857.477 58.73%
2021 -195.300.000 36.07%
2022 -263.200.000 25.8%
2023 -295.600.000 10.96%
2023 -394.800.000 25.13%
2024 -187.200.000 -110.9%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Arvinas, Inc. Gross Profit
Year Gross Profit Growth
2016 6.669.024
2017 7.578.876 12.01%
2018 14.323.920 47.09%
2019 42.976.478 66.67%
2020 21.801.777 -97.12%
2021 40.700.000 46.43%
2022 123.200.001 66.96%
2023 138.400.000 10.98%
2023 71.800.000 -92.76%
2024 299.200.000 76%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Arvinas, Inc. Net Profit
Year Net Profit Growth
2016 -14.350.643
2017 -24.049.206 40.33%
2018 -41.480.466 42.02%
2019 -62.132.038 33.24%
2020 -111.786.706 44.42%
2021 -183.200.000 38.98%
2022 -271.900.000 32.62%
2023 -256.000.000 -6.21%
2023 -367.300.000 30.3%
2024 -140.800.000 -160.87%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Arvinas, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 -1
2017 -1 100%
2018 -4 75%
2019 -2 -300%
2020 -3 50%
2021 -4 33.33%
2022 -5 40%
2023 -5 -25%
2023 -7 33.33%
2024 -2 -500%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Arvinas, Inc. Free Cashflow
Year Free Cashflow Growth
2016 -19.709.796
2017 4.100.666 580.65%
2018 -18.948.331 121.64%
2019 -46.870.366 59.57%
2020 -96.204.467 51.28%
2021 554.700.000 117.34%
2022 -280.300.000 297.9%
2023 -85.900.000 -226.31%
2023 -350.700.000 75.51%
2024 49.600.000 807.06%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Arvinas, Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -19.403.129
2017 5.113.094 479.48%
2018 -16.117.670 131.72%
2019 -40.626.342 60.33%
2020 -89.756.934 54.74%
2021 559.400.000 116.05%
2022 -273.500.000 304.53%
2023 -84.800.000 -222.52%
2023 -347.800.000 75.62%
2024 50.300.000 791.45%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Arvinas, Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 306.667
2017 1.012.428 69.71%
2018 2.830.661 64.23%
2019 6.244.024 54.67%
2020 6.447.533 3.16%
2021 4.700.000 -37.18%
2022 6.800.000 30.88%
2023 1.100.000 -518.18%
2023 2.900.000 62.07%
2024 700.000 -314.29%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Arvinas, Inc. Equity
Year Equity Growth
2016 24.031.100
2017 245.870 -9673.9%
2018 136.666.983 99.82%
2019 226.686.281 39.71%
2020 642.257.512 64.7%
2021 781.700.000 17.84%
2022 564.900.000 -38.38%
2023 457.200.000 -23.56%
2023 660.000.000 30.73%
2024 600.200.000 -9.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Arvinas, Inc. Assets
Year Assets Growth
2016 37.936.882
2017 66.848.369 43.25%
2018 199.281.575 66.46%
2019 301.641.426 33.93%
2020 717.368.587 57.95%
2021 1.581.600.000 54.64%
2022 1.268.800.000 -24.65%
2023 1.058.300.000 -19.89%
2023 1.304.600.000 18.88%
2024 1.279.600.000 -1.95%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Arvinas, Inc. Liabilities
Year Liabilities Growth
2016 13.905.782
2017 66.602.499 79.12%
2018 62.614.592 -6.37%
2019 74.955.145 16.46%
2020 75.111.075 0.21%
2021 799.900.000 90.61%
2022 703.900.000 -13.64%
2023 601.100.000 -17.1%
2023 644.600.000 6.75%
2024 679.400.000 5.12%

Arvinas, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.3
Net Income per Share
-4.5
Price to Earning Ratio
-5.73x
Price To Sales Ratio
18.97x
POCF Ratio
-8.62
PFCF Ratio
-8.15
Price to Book Ratio
3.09
EV to Sales
17.27
EV Over EBITDA
-4.4
EV to Operating CashFlow
-7.49
EV to FreeCashFlow
-7.42
Earnings Yield
-0.17
FreeCashFlow Yield
-0.12
Market Cap
1,77 Bil.
Enterprise Value
1,61 Bil.
Graham Number
29.07
Graham NetNet
7.82

Income Statement Metrics

Net Income per Share
-4.5
Income Quality
0.67
ROE
-0.56
Return On Assets
-0.25
Return On Capital Employed
-0.4
Net Income per EBT
1.01
EBT Per Ebit
0.87
Ebit per Revenue
-3.98
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
1.13
Research & Developement to Revenue
3.85
Stock Based Compensation to Revenue
0.79
Gross Profit Margin
0.93
Operating Profit Margin
-3.98
Pretax Profit Margin
-3.44
Net Profit Margin
-3.47

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.99
Free CashFlow per Share
-3.02
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.02
Capex to Depreciation
0.29
Return on Invested Capital
-0.62
Return on Tangible Assets
-0.25
Days Sales Outstanding
39.12
Days Payables Outstanding
1234.56
Days of Inventory on Hand
0
Receivables Turnover
9.33
Payables Turnover
0.3
Inventory Turnover
0
Capex per Share
0.03

Balance Sheet

Cash per Share
17,17
Book Value per Share
8,35
Tangible Book Value per Share
8.35
Shareholders Equity per Share
8.35
Interest Debt per Share
0.13
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.43
Current Ratio
3.62
Tangible Asset Value
0,60 Bil.
Net Current Asset Value
0,58 Bil.
Invested Capital
920800000
Working Capital
0,91 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,02 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Arvinas, Inc. Dividends
Year Dividends Growth

Arvinas, Inc. Profile

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CEO
Dr. John G. Houston Ph.D.
Employee
445
Address
5 Science Park
New Haven, 06511

Arvinas, Inc. Executives & BODs

Arvinas, Inc. Executives & BODs
# Name Age
1 Mr. Jared M. Freedberg J.D.
General Counsel & Corporate Secretary
70
2 Mr. Steve Weiss
Senior Vice President & Chief Human Resources Officer
70
3 Dr. Randy Teel Ph.D.
Chief Business Officer
70
4 Mr. Andrew R. Saik
Chief Financial Officer & Treasurer
70
5 Mr. David K. Loomis M.B.A.
Vice President, Chief Accounting Officer & Corporate Controller
70
6 Dr. John A. Grosso Ph.D.
Senior Vice President of R&D Technical Operations
70
7 Ms. Angela M. Cacace Ph.D.
Chief Scientific Officer
70
8 Dr. John G. Houston Ph.D.
Chairperson, Chief Executive Officer & President
70
9 Mr. Jeff Boyle
Vice President of Investor Relations
70
10 Dr. Ian Taylor Ph.D.
President of Research & Development and Chairman of Scientific Advisory Board
70

Arvinas, Inc. Competitors